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Abstract
Objective
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized with joint
destructions; environmental and genetic factors were thought to be involved in the etiology
of RA. The production of anti-citrullinated peptide antibodies (ACPA) is specifically associ-
ated with RA. DRB1 is associated with the susceptibility of RA, especially ACPA-positive
RA [ACPA(+)RA]. However, a few studies reported on the independent associations of
DPB1 alleles with RA susceptibility. Thus, we investigated the independent association of
DPB1 alleles with RA in Japanese populations.
Methods
Association analyses of DPB1 were conducted by logistic regression analysis in 1667 RA
patients and 413 controls.
Results
In unconditioned analysis, DPB1*04:02 was nominally associated with the susceptibility of
ACPA(+)RA (P = 0.0021, corrected P (Pc) = 0.0275, odds ratio [OR] 1.52, 95% confidence
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interval [CI] 1.16–1.99). A significant association of DPB1*02:01 with the susceptibility of
ACPA(+)RA was observed, when conditioned on DRB1 (Padjusted = 0.0003, Pcadjusted =
0.0040, ORadjusted 1.47, 95%CI 1.19–1.81). DPB1*05:01 was tended to be associated
with the protection against ACPA(+)RA, when conditioned on DRB1 (Padjusted = 0.0091,
Pcadjusted = 0.1184, ORadjusted 0.78, 95%CI 0.65–0.94). When conditioned on DRB1, the
association of DPB1*04:02 with ACPA(+)RA was disappeared. No association of DPB1
alleles with ACPA-negative RA was detected.
Conclusion
The independent association of DPB1*02:01 with Japanese ACPA(+)RA was identified.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized with synovial joint
destructions and extra-articular manifestations. The etiology of RA is still unknown, but envi-
ronmental and genetic factors were thought to be involved in the pathogenesis of RA [1,2,3].
Human leukocyte antigen (HLA) is the strongest genetic factor in RA and it was confirmed in
genome wide association studies based on single nucleotide polymorphisms [4]. DRB1 was
believed to be the most important locus in HLA for the susceptibility of RA; some DRB1 alleles
were associated with the susceptibility of RA and have common motifs of amino acid residues
at position 70–74 (QKRAA, RRRAA, or QRRAA) in DRβ chain [5]. These were designated as
shared epitope (SE) alleles [6]. DRB104:01was mainly associated with RA in European popu-
lations [5] and DRB104:05 in Asian [7]. Although both of DRB104:01 and DRB104:05 are SE
alleles, these differences could be explained by the different frequencies of these susceptibility
alleles for RA in different ethnic groups. The production of anti-citrullinated peptide antibod-
ies (ACPA) is specifically associated with RA. ACPA-positive RA [ACPA(+)RA] is strongly
associated with SE alleles, but ACPA-negative RA [ACPA(-)RA] is weakly [7,8,9].
Some reports also suggested that B, DQB1, or DPB1 would be involved in the pathogenesis
of RA [10,11,12,13,14,15,16,17,18,19,20]. Since HLA region is in strong linkage disequilibrium,
it is important to eliminate the effects of DRB1 to elucidate the role of other loci in HLA. The
independent associations of amino acid residues in B and DPB1 loci were recently reported
[21,22,23]. However, few studies reported on the independent associations of DPB1 alleles for
RA susceptibility. Since DRB1 is the strongest genetic risk factor for ACPA(+)RA, we investi-
gated the independent association of DPB1 alleles from DRB1 in Japanese ACPA(+)RA.
Materials and methods
Patients
One thousand six hundred sixty seven Japanese RA patients were recruited at Hyogo College
of Medicine, Jichi Medical University, Miyakonojo Medical Center, Nagasaki Medical Center,
Nagoya Medical Center, Niigata Rheumatic Center, Sagamihara National Hospital, Tochigi
Rheumatology Clinic, Tokyo Metropolitan Tama Medical Center, or Yokohama Minami Kyo-
sai Hospital. RA patients fulfilled the 1987 American College of Rheumatology criteria for RA
[24] or the 2010 Rheumatoid Arthritis Classification Criteria [25]. Four hundred thirteen Japa-
nese healthy controls (mean age ± SD, 39.3 ± 11.0 years, vs. ACPA(+)RA: P = 6.50X10-130, vs.
ACPA(-)RA, P = 5.51X10-71, 61 male [14.8%], vs. ACPA(+)RA: P = 0.0792, vs. ACPA(-)RA,
DPB1*02:01 in Japanese RA
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P = 0.2195) were recruited at Kanazawa University, Sagamihara National Hospital, and Teikyo
University [26] or by the Pharma SNP Consortium (Tokyo, Japan) [27,28]. Rheumatoid factor
and ACPA were measured by N-latex RF kit (Siemens Healthcare Diagnostics, Mu¨nchen, Ger-
many) or Mesacup-2 test CCP (Medical & Biological Laboratories, Nagoya, Japan), respec-
tively. This study was reviewed and approved by Hyogo College of Medicine Research Ethics
Committee, Jichi Medical University Research Ethics Committee, Miyakonojo Medical Center
Research Ethics Committee, Nagasaki Medical Center Research Ethics Committee, Nagoya
Medical Center Research Ethics Committee, Niigata Rheumatic Center Research Ethics Com-
mittee, Sagamihara National Hospital Research Ethics Committee, Tokyo Metropolitan Tama
Medical Center Research Ethics Committee, Yokohama Minami Kyosai Hospital Research
Ethics Committee, and University of Tsukuba Research Ethics Committee. Written informed
consent was obtained from all study participants. This study was conducted in accordance
with the principles expressed in the Declaration of Helsinki.
Genotyping of DRB1 and DPB1
Genotyping of DRB1 and DPB1 was performed by polymerase chain reaction with reverse
sequence-specific oligonucleotide probes (WAKFlow HLA typing kit, Wakunaga Pharmaceu-
tical Co., Ltd., Akitakata, Japan) and Bio-Plex 200 (Bio-Rad, Hercules, CA). SE alleles contain
DRB101:01,DRB104:01,DRB104:05,DRB104:10,DRB110:01, and DRB114:06 [5]. Geno-
typing results for some of the RA patients and the healthy controls were previously reported
[7,26,29,30,31,32].
Statistical analysis
Clinical features of the RA patients were analyzed by Fisher’s exact test using 2X2 contingency
tables or Student’s t-test. Unconditioned logistic regression analysis under the additive model
was performed to analyze nominal associations of HLA alleles with the susceptibility of RA.
On the other hand, conditioned logistic regression analysis was used to investigate the inde-
pendent contribution of each DPB1 allele from DRB1 to the susceptibility of RA. Padjusted and
ORadjusted were calculated for DPB1 alleles, when conditioned on DRB1. Alleles detected in
both case and control groups were tested. The two-locus analysis was also conducted by logis-
tic regression analysis under the additive model to identify the primary role of associated
DRB1 or DPB1 alleles. Haplotype frequencies of DRB1-DPB1 were estimated with expectation-
maximization algorithm with SNPAlyze ver.8.0.4 Pro (Dynacom, Chiba, Japan) and Permuta-
tion P values were established by 100000 permutations. Logistic regression analysis under the
additive model was also performed to analyze associations of amino acid residues; conditional
logistic regression analysis was used to investigate the independent contribution of each DPβ
chain amino acid residue from DRβ chain amino acid residues to the susceptibility of RA.
Padjusted values were calculated for amino acid residues in the DPβ chains, when conditioned
on DRβ chain amino acid residues. Multiple comparisons were adjusted by Bonferroni
method; corrected P (Pc) values were derived from multiplying the P values by the number of
alleles or amino acid residues tested.
Results
Clinical manifestations of RA patients
Characteristics of RA patients are shown in Table 1. Steinbrocker stage and class [33] were
higher in ACPA(+)RA than ACPA(-)RA. The rheumatoid factor positivity rate was also
higher.
DPB1*02:01 in Japanese RA
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Association of DPB1 with ACPA(+)RA
Association of DRB1 with ACPA(+)RA was confirmed (S1 Table), as reported in the previous
study [7]; DRB104:05 and 04:01were associated with the susceptibility of ACPA(+)RA and
DRB104:06, 08:02, 08:03, 13:02, and 14:03were protectively associated. Next, it was ana-
lyzed whether DPB1 was also associated with ACPA(+)RA (Table 2). In unconditioned analy-
sis, DPB104:02was nominally associated with the susceptibility of ACPA(+)RA (P = 0.0021,
Pc = 0.0275, odds ratio [OR] 1.52, 95% confidence interval [CI] 1.16–1.99, Table 2, left col-
umn). Since DRB1 and DPB1 are in strong linkage disequilibrium, nominal associations of
DPB1 alleles were influences by the associations of DRB1 alleles with ACPA(+)RA. In order to
Table 1. Characteristics of RA patients.
ACPA(+)RA ACPA(-)RA P
Number 1436 231
Mean age, years (SD) 62.8 (12.3) 61.8 (12.5) 0.2991
Male, n (%) 267 (18.7) 43 (18.7) 1.0000
Age at onset (SD) 49.8 (14.3) 51.9 (16.0) 0.0850
Steinbrocker stage III and IV, n (%) 629 (48.6) 61 (31.8) 1.26X10-5
Steinbrocker class 3 and 4, n (%) 195 (15.1) 15 (7.9) 0.0072
Rheumatoid factor positive, n (%) 1192 (88.8) 79 (37.4) 1.86X10-56
RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, ACPA(-)RA:
ACPA negative RA. Association was tested between ACPA(+)RA and ACPA(-)RA by Fisher’s exact test using 2X2
contingency tables or Student’s t-test.
Student’s t-test was employed.
https://doi.org/10.1371/journal.pone.0204459.t001
Table 2. Conditional logistic regression analysis of DPB1 alleles in ACPA(+) RA and controls.
Uncoditioned Conditioned on DRB1
DPB1 allele ACPA(+)RA
(2n = 2872)
Control
(2n = 826)
OR 95%CI P Pc ORadjusted 95%CI Padjusted Pcadjusted
DPB102:01 781 (27.2) 198 (24.0) 1.19 (0.99–1.42) 0.0644 0.8371 1.47 (1.19–1.81) 0.0003 0.0040
DPB102:02 119 (4.1) 34 (4.1) 1.01 (0.68–1.49) 0.9723 NS 1.09 (0.69–1.72) 0.6998 NS
DPB103:01 113 (3.9) 36 (4.4) 0.91 (0.62–1.33) 0.6150 NS 0.80 (0.52–1.24) 0.3141 NS
DPB104:01 98 (3.4) 44 (5.3) 0.64 (0.45–0.92) 0.0147 0.1909 1.00 (0.58–1.72) 0.9912 NS
DPB104:02 351 (12.2) 69 (8.4) 1.52 (1.16–1.99) 0.0021 0.0275 1.12 (0.79–1.58) 0.5362 NS
DPB105:01 1054 (36.7) 319 (38.6) 0.92 (0.78–1.08) 0.3114 NS 0.78 (0.65–0.94) 0.0091 0.1184
DPB106:01 15 (0.5) 3 (0.4) 1.44 (0.42–5.01) 0.5638 NS 2.15 (0.56–8.22) 0.2640 NS
DPB109:01 218 (7.6) 87 (10.5) 0.70 (0.54–0.91) 0.0072 0.0930 0.67 (0.40–1.10) 0.1132 NS
DPB113:01 36 (1.3) 19 (2.3) 0.53 (0.30–0.94) 0.0297 0.3862 0.57 (0.31–1.06) 0.0782 NS
DPB114:01 44 (1.5) 8 (1.0) 1.60 (0.75–3.43) 0.2262 NS 1.06 (0.45–2.48) 0.9019 NS
DPB117:01 6 (0.2) 3 (0.4) 0.57 (0.14–2.30) 0.4330 NS 0.49 (0.05–5.05) 0.5478 NS
DPB119:01 13 (0.5) 2 (0.2) 1.88 (0.42–8.35) 0.4082 NS 1.08 (0.23–5.08) 0.9216 NS
DPB141:01 7 (0.2) 2 (0.2) 1.01 (0.21–4.86) 0.9934 NS 0.87 (0.14–5.48) 0.8826 NS
RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds ratio, CI: confidence interval, Pc: corrected P value,
NS: not significant. Allele frequencies are shown in parenthesis (%).The association of each DPB1 allele with ACPA(+)RA was analyzed by logistic regression analysis.
The left column indicates the results from unconditioned analyses. The right column indicates the results from analyses conditioned on DRB1. Padjusted and ORadjusted
were calculated by conditional logistic regression analysis under the additive model. Corrected P (Pc) values were calculated by multiplying the P value by the number of
alleles tested.
https://doi.org/10.1371/journal.pone.0204459.t002
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clarify whether each DPB1 allele was independently associated with ACPA(+)RA, conditional
logistic regression analysis was performed (Table 2, right column). The significant association
of DPB102:01with the susceptibility of ACPA(+)RA was observed, when conditioned on
DRB1 (Padjusted = 0.0003, Pcadjusted = 0.0040, ORadjusted 1.47, 95%CI 1.19–1.81, Table 2, right
column). DPB105:01was tended to be associated with the protection against ACPA(+)RA,
when conditioned on DRB1 (Padjusted = 0.0091, Pcadjusted = 0.1184, ORadjusted 0.78, 95%CI
0.65–0.94, Table 2, right column). When conditioned on DRB1, DPB104:02was not associ-
ated with the susceptibility of ACPA(+)RA, suggesting the influence of DRB1 on the nominal
association of DPB104:02. Thus, DPB102:01was independently associated with the suscepti-
bility of ACPA(+)RA.
In order to reveal whether each DRB1 allele influenced on the association of DPB102:01
with the susceptibility of ACPA(+)RA, conditional logistic regression analysis was conducted
(Table 3). When conditioned on DRB104:05, the significant association of DPB102:01with
the susceptibility of ACPA(+)RA was observed (Padjusted = 0.0073, ORadjusted 1.29, 95%CI 1.07–
1.56, Table 3). Because DRB104:05 is the strongest risk factor for RA in Asian [7], the influ-
ence of DRB104:05 on the nominal association of DPB102:01would be strongest. However,
the stronger association of DPB102:01with the susceptibility of ACPA(+)RA was observed,
when conditioned on SE alleles (Padjusted = 0.0016, ORadjusted 1.37, 95%CI 1.13–1.66, Table 3)
or DRB1 (Padjusted = 0.0003, ORadjusted 1.47, 95%CI 1.19–1.81, Table 3). These data suggested
that many DRB1 alleles including DRB104:05 had influenced on the nominal association of
DPB102:01with the susceptibility of ACPA(+)RA.
The two-locus analysis was conducted to identify the primary role of DRB104:05 and
DPB102:01 for the susceptibility of ACPA(+)RA (S2 Table). The OR for DPB102:01 in
ACPA(+)RA patients with DRB104:05was 1.45 (P = 0.0688, S2 Table), while the OR for
DPB102:01 in ACPA(+)RA patients without DRB104:05was 1.26 (P = 0.0356, S2 Table). On
the other hand, the OR for DRB104:05 in ACPA(+)RA patients with DPB102:01was 4.21
(P = 3.71X10-12, S2 Table), and the OR for DRB104:05 in ACPA(+)RA patients without
DPB102:01was 3.33 (P = 7.58X10-15, S2 Table). These results suggested the independent roles
of DRB104:05 and DPB102:01 on the susceptibility of ACPA(+)RA.
When haplotype frequencies were compared between ACPA(+)RA patients and controls,
three haplotypes including DRB104:05were associated with the susceptibility of ACPA(+)RA
(DRB104:05-DPB102:01; Permutation P<0.0001, DRB104:05-DPB104:02,; Permutation
P = 0.0004, DRB104:05-DPB105:01; Permutation P<0.0001, S3 Table), suggesting the pri-
mary role of DRB104:05. On the other hand, some haplotypes including DPB102:01were
associated with the ACPA(+)RA susceptibility (DRB104:05-DPB102:01; Permutation P
<0.0001, DRB109:01-DPB102:01; Permutation P = 0.0048, S3 Table) or the protection
(DRB104:06-DPB102:01; Permutation P = 0.0149, DRB108:02-DPB102:01; Permutation
P<0.0001, DRB113:02-DPB102:01; Permutation P = 0.0015, DRB115:01-DPB102:01; Per-
mutation P = 0.0208, S3 Table), suggesting the influences of DRB1 alleles on the effects of
DPB102:01. These data suggested the stronger effects of DRB1 alleles on the ACPA(+)RA sus-
ceptibility or the protection.
Association of DPB1 with ACPA(-)RA
It was analyzed whether DPB1 was also associated with ACPA(-)RA (Table 4). In uncondi-
tioned analysis, no DPB1 allele was associated with the susceptibility of ACPA(-)RA (Table 4,
left column). In order to elucidate whether each DPB1 allele was independently associated
with ACPA(-)RA, conditional logistic regression analysis was performed (Table 4, right col-
umn). No association of DPB1 alleles with the susceptibility of ACPA(-)RA was observed,
DPB1*02:01 in Japanese RA
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when conditioned on DRB1. Association of DPB1 was also analyzed with overall RA (S4
Table). In unconditioned analysis, no DPB1 allele was associated with the overall RA (S4
Table, left column). When conditioned on DRB1, DPB102:01was associated with the overall
RA (S4 Table, right column). However, the association was weaker than ACPA(+)RA.
Association of DPβ chain amino acid residues with ACPA(+)RA
Association of DRβ chain amino acid residues with ACPA(+)RA was confirmed (S1 Fig), as
reported in the previous study [7]; 10Y, 11S, 12T, 13H, 33N, 70D, 96Y, and 98K in the DRβ
chain showed associations. Two amino acid residues, 36A 55A, in the DPβ chain were slightly
Table 3. Conditional logistic regression analysis of DPB102:01 between ACPA(+) RA and controls.
Uncoditioned
OR 95%CI P
1.19 (0.99–1.42) 0.0644
Conditioned on each DRB1 allele
ORadjusted 95%CI Padjusted
DRB101:01 1.22 (1.02–1.47) 0.0307
DRB104:01 1.17 (0.97–1.40) 0.0934
DRB104:03 1.20 (1.00–1.43) 0.0507
DRB104:05 1.29 (1.07–1.56) 0.0073
DRB104:06 1.25 (1.04–1.51) 0.0165
DRB104:07 1.19 (0.99–1.42) 0.0590
DRB104:10 1.19 (0.99–1.42) 0.0596
DRB107:01 1.18 (0.99–1.42) 0.0655
DRB108:02 1.22 (1.01–1.46) 0.0359
DRB108:03 1.20 (1.00–1.43) 0.0520
DRB109:01 1.18 (0.98–1.41) 0.0740
DRB110:01 1.17 (0.98–1.40) 0.0844
DRB111:01 1.19 (0.99–1.42) 0.0596
DRB112:01 1.18 (0.98–1.41) 0.0776
DRB112:02 1.19 (0.99–1.42) 0.0644
DRB113:01 1.20 (1.00–1.44) 0.0454
DRB113:02 1.16 (0.97–1.39) 0.1052
DRB114:03 1.21 (1.01–1.46) 0.0366
DRB114:05 1.18 (0.98–1.41) 0.0727
DRB114:06 1.19 (0.99–1.42) 0.0625
DRB114:07 1.18 (0.99–1.42) 0.0664
DRB114:54 1.18 (0.98–1.41) 0.0733
DRB115:01 1.21 (1.01–1.46) 0.0373
DRB115:02 1.16 (0.96–1.39) 0.1171
DRB116:02 1.19 (0.99–1.42) 0.0628
SE 1.37 (1.13–1.66) 0.0016
DRB1 1.47 (1.19–1.81) 0.0003
RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds
ratio, CI: confidence interval, SE: Shared epitope. The association of DPB102:01 with ACPA(+) RA was analyzed by
logistic regression analysis. The first row indicates the results from unconditioned analyses. The other rows indicate
the results from analyses conditioned on shown DRB1 alleles. Padjusted and ORadjusted were calculated by conditional
logistic regression analysis under the additive model.
https://doi.org/10.1371/journal.pone.0204459.t003
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associated with ACPA(+)RA in unconditioned analysis (Fig 1A). In order to clarify whether
each DPβ chain amino acid residue was independently associated with ACPA(+)RA,
conditional logistic regression analysis was performed. Five amino acid residues, 84G
(P = 3.20X10-5, Pc = 0.0005, OR = 1.48, 95% CI 1.23–1.79), 85G (P = 3.20X10-5, Pc = 0.0005,
OR = 1.48, 95% CI 1.23–1.79), 86P (P = 3.20X10-5, Pc = 0.0005, OR = 1.48, 95% CI 1.23–1.79),
87M (P = 3.20X10-5, Pc = 0.0005, OR = 1.48, 95% CI 1.23–1.79), and 96R (P = 3.94X10-5,
Pc = 0.0006, OR = 1.48, 95% CI 1.23–1.78), in the DPβ chain were significantly associated with
ACPA(+)RA, when conditioned on DRβ chain amino acid residues (Fig 1B). Since there are
three haplotypes of these amino acid residues in the DPβ chain (84G-85G-86P-87M-96R,
84D-85E-86A-87V-96K, 84D-85E-86A-87V-96R), the results might reflect the effects of the
haplotype of 84G-85G-86P-87M-96R on the susceptibility of ACPA(+)RA. The haplotype was
actually associated with ACPA(+)RA in unconditioned analysis (P = 0.0078, OR = 1.24, 95%
CI 1.06–1.44), or when conditioned on DRβ chain amino acid residues (Padjusted = 4.11X10-5,
ORadjusted 1.47, 95%CI 1.22–1.77).
Discussion
Although many investigations on the associations of DRB1 alleles with the susceptibility of RA
were performed, relatively fewer studies on the genetic effects of DPB1 alleles for RA were con-
ducted. There are a few direct reports on the independent association of DPB1 alleles for the
susceptibility of RA, though results of some studies suggested the role of DPB1 alleles for RA
[10,13,14,16,18]. DPB103:01was associated with rheumatoid factor negative RA in European
descent [10]. When arginine at position 71 of DRβ chain was possessed, DPB104:01was asso-
ciated with European RA [13]. DPB102:01 and DPB106:01were associated with European
RA without SE, whereas DPB104:01was associated with European RA with SE [14].
DPB102:01was associated with Japanese RA without DRB104:05 [16]. The association of
DPB102:01with the susceptibility of Japanese ACPA(+)RA and that of DPB104:01and
Table 4. Conditional logistic regression analysis of DPB1 alleles between ACPA(-)RA and controls.
Uncoditioned Conditioned on DRB1
DPB1 allele ACPA(-)RA
(2n = 462)
Control
(2n = 826)
OR 95%CI P Pc ORadjusted 95%CI Padjusted Pcadjusted
DPB102:01 118 (25.5) 198 (24.0) 1.09 (0.84–1.42) 0.5270 NS 1.20 (0.90–1.60) 0.2238 NS
DPB102:02 12 (2.6) 34 (4.1) 0.62 (0.32–1.21) 0.1645 NS 0.64 (0.31–1.33) 0.2277 NS
DPB103:01 21 (4.5) 36 (4.4) 1.05 (0.60–1.82) 0.8750 NS 0.86 (0.47–1.58) 0.6332 NS
DPB104:01 19 (4.1) 44 (5.3) 0.77 (0.45–1.32) 0.3456 NS 0.77 (0.36–1.64) 0.4931 NS
DPB104:02 42 (9.1) 69 (8.4) 1.10 (0.73–1.65) 0.6486 NS 0.88 (0.53–1.46) 0.6201 NS
DPB105:01 190 (41.1) 319 (38.6) 1.10 (0.88–1.39) 0.3891 NS 1.00 (0.77–1.30) 0.9834 NS
DPB106:01 3 (0.6) 3 (0.4) 1.80 (0.36–8.98) 0.4746 NS 1.69 (0.31–9.30) 0.5491 NS
DPB109:01 36 (7.8) 87 (10.5) 0.72 (0.48–1.08) 0.1137 NS 0.88 (0.44–1.74) 0.7097 NS
DPB113:01 10 (2.2) 19 (2.3) 0.94 (0.43–2.05) 0.8734 NS 0.94 (0.41–2.15) 0.8856 NS
DPB114:01 6 (1.3) 8 (1.0) 1.35 (0.46–3.94) 0.5829 NS 1.47 (0.44–4.98) 0.5326 NS
DPB117:01 1 (0.2) 3 (0.4) 0.59 (0.06–5.75) 0.6530 NS 2.07 (0.09–47.37) 0.6493 NS
DPB141:01 3 (0.6) 2 (0.2) 2.70 (0.45–16.30) 0.2778 NS 2.43 (0.37–15.87) 0.3554 NS
RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(-)RA: ACPA negative RA, OR: odds ratio, CI: confidence interval, Pc: corrected P value, NS:
not significant. Allele frequencies are shown in parenthesis (%). Association was tested between ACPA(-) RA and controls by logistic regression analysis. Padjusted and
ORadjusted were calculated by conditional logistic regression analysis under the additive model. Corrected P (Pc) values were calculated by multiplying the P value by the
number of alleles tested.
https://doi.org/10.1371/journal.pone.0204459.t004
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DPB109:01with the protection were suggested [18]. However, the results of these previous
studies could not conclude the independent association of DPB102:01 from DRB1. In the
present study, we directly revealed it in Japanese populations.
It was reported that phenylalanine at position 9 in DPβ chain was reported to be indepen-
dently associated with European ACPA(+)RA [21]. Glycine at position 84 in DPβ chain was
also independently associated with Japanese ACPA(+)RA [23]. However, the independently
Fig 1. Associations of amino acid residues in the DPβ chains with ACPA(+)RA. (A) Association was established
between ACPA(+)RA and controls by logistic regression analysis. (B) Conditional logistic regression analysis was
performed to clarify whether each DPβ chain amino acid residue was independently associated with ACPA(+)RA.
Padjusted values were calculated for amino acid residues in the DPβ chains, when conditioned on DRβ chain amino acid
residues. Corrected P (Pc) values were obtained by multiplying the P value by the number of amino acid residues
tested. RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA.
https://doi.org/10.1371/journal.pone.0204459.g001
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associated DPB1 alleles were not reported in these studies. In the present study, glycine at
position 84 in DPβ chain was independently associated with ACPA(+)RA and 84G-85G-
86P-87M-96R in DPβ chain was the ACPA(+)RA susceptible haplotype. This ACPA(+)RA
associated haplotype was included in DPB102:01, DPB102:02, DPB104:01, DPB104:02,
and DPB141:01. Since the alleles other than DPB102:01 were not directly associated
with ACPA(+)RA susceptibility (Table 2, right column), DPB102:01 would be mainly con-
tributed to the risk of ACPA(+)RA among them. The independent association of phenylala-
nine at position 9 in DPβ chain was not confirmed in the present study, though this amino
acid residue was included in DPB102:01 and other alleles. This could be explained by the
different distribution of HLA alleles in other ethnic populations. The amino acid residues 84,
85, 86, and 87 form the pocket 1 of DP peptide-binding groove [34]. This information sug-
gested the involvement of peptides loaded on DP2 in the generation of ACPA or rheumatoid
factor.
The association of DPB102:01with ACPA(-)RA was not detected in the present study
(Table 4), because of the limited sample size of ACPA(-)RA. Although the association of
DPB1with ACPA(-)RA was not found in the study on European populations [22], weak associ-
ation was shown around DP loci in the other study on Japanese populations [23]. Therefore,
this could be detected in future large scale studies. The independent association of DPB102:01
with ACPA(+)RA should be replicated in future studies in Japanese populations and should be
also analyzed in other populations. It was the limitation of this study that the population strati-
fication was not excluded [35,36]. Thus, the present study revealed the independent associa-
tion of DPB102:01with ACPA(+)RA in Japanese populations.
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